1,881 Shares in Becton, Dickinson and Company $BDX Purchased by Callan Family Office LLC

Key Points

• Callan Family Office LLC recently acquired 1,881 shares of Becton, Dickinson and Company, totaling approximately $324,000, as revealed in their SEC filing.
• Institutional investors dominate Becton, Dickinson and Company, holding 86.97% of the stock, with Vanguard Group being the largest shareholder with over $6.4 billion in holdings.
• Becton, Dickinson and Company has been rated with an average of "Hold" by analysts, with recent price targets ranging from $205.40 to $230.00.

Callan Family Office LLC purchased a new position in Becton, Dickinson and Company (NYSE:BDX - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,881 shares of the medical instruments supplier's stock, valued at approximately $324,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Becton, Dickinson and Company by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock worth $6,414,322,000 after buying an additional 1,259,750 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its stake in Becton, Dickinson and Company by 3.7% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier's stock valued at $2,880,510,000 after acquiring an additional 448,644 shares during the period. Massachusetts Financial Services Co. MA raised its stake in Becton, Dickinson and Company by 10.8% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock valued at $1,567,654,000 after acquiring an additional 667,957 shares during the period. JPMorgan Chase & Co. raised its stake in Becton, Dickinson and Company by 7.6% in the 1st quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier's stock valued at $1,012,649,000 after acquiring an additional 312,124 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in Becton, Dickinson and Company by 1.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,091,149 shares of the medical instruments supplier's stock valued at $707,872,000 after acquiring an additional 37,733 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

BDX has been the topic of a number of research reports. Weiss Ratings restated a "hold (c-)" rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Royal Bank Of Canada initiated coverage on Becton, Dickinson and Company in a research note on Thursday, September 25th. They issued a "sector perform" rating and a $211.00 price objective on the stock. Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Argus boosted their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Finally, Wells Fargo & Company upped their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research report on Friday, August 8th. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $205.40.

Becton, Dickinson and Company Stock Down 0.8%

Shares of NYSE BDX opened at $186.76 on Thursday. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $53.53 billion, a price-to-earnings ratio of 33.59, a PEG ratio of 1.47 and a beta of 0.25. The business has a 50-day moving average of $190.74 and a 200-day moving average of $185.48.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.32 billion during the quarter. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were paid a $1.04 dividend. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio is currently 74.82%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the company's stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares of the company's stock, valued at $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Claire Fraser sold 917 shares of the company's stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company's stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,023 shares of company stock valued at $562,036. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.